SRR15069607
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.430
- MYC_TARGETS_V1+0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- E2F_TARGETS+0.290
- SPERMATOGENESIS+0.180
- MTORC1_SIGNALING+0.170
- OXIDATIVE_PHOSPHORYLATION+0.160
- G2M_CHECKPOINT+0.150
- DNA_REPAIR+0.140
- PANCREAS_BETA_CELLS+0.050
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.650
- INTERFERON_GAMMA_RESPONSE-0.570
- IL6_JAK_STAT3_SIGNALING-0.460
- ALLOGRAFT_REJECTION-0.450
- INFLAMMATORY_RESPONSE-0.440
- COMPLEMENT-0.420
- TGF_BETA_SIGNALING-0.420
- TNFA_SIGNALING_VIA_NFKB-0.410
- NOTCH_SIGNALING-0.400
- ANGIOGENESIS-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A5RZ-01A-11R-A28M-07 | — | C | 0.916 |
| 2 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.916 |
| 3 | C3N-01017 | — | cohortSQ2 | 0.913 |
| 4 | TCGA-AN-A0AR-01A-11R-A00Z-07 | — | E | 0.910 |
| 5 | SRR8518240 | — | E | 0.905 |
| 6 | SRR25043617 | — | — | 0.900 |
| 7 | BS_ZXYDSBM9 | medulloblastoma | — | 0.899 |
| 8 | BS_9NZ2D6AD | medulloblastoma | — | 0.899 |
| 9 | BS_JZRM1S3T | medulloblastoma | — | 0.898 |
| 10 | TCGA-63-A5MY-01A-11R-A26W-07 | — | cohortSQ2 | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |